From CNN Brasil · Helena Barra · · 50s
Experimental Vaccine Extends Life in Severe Leukemia Cases
Experimental leukemia vaccine boosts survival by over nine months for severe blood cancer patients.
In brief
Experimental leukemia vaccine boosts survival by over nine months for severe blood cancer patients. A new experimental vaccine for acute myeloid leukemia significantly increases median survival from 14.7 to 24 months in patients who completed chemotherapy. Originally reported by CNN Brasil.
Experimental Vaccine Boosts Survival
A new experimental vaccine for acute myeloid leukemia significantly increases median survival from 14.7 to 24 months in patients who completed chemotherapy.
How the Vaccine Works
The vaccine trains the patient's immune system to recognize and destroy residual cancer cells after chemotherapy.
Key Results of Study

The study showed a 41% reduction in mortality risk and a median survival of 24 months for patients receiving the vaccine.
Next Steps for Approval
SELLAS Life Sciences plans to discuss FDA approval pathways with the U.S. agency by early 2027.
The headline
A new experimental vaccine for acute myeloid leukemia significantly increases median survival from 14.7 to 24 months in patients who completed chemotherapy.
Read the TL;DR — this story on one card.





